Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3 Recruiting
186 enrolled
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
290 enrolled
A Study of KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment in Patients With Advanced Esophageal Cancer
Phase 2 Recruiting
60 enrolled
VELOCITY-Lung
Phase 2 Recruiting
270 enrolled
RAMP 301
Phase 3 Recruiting
270 enrolled
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2/3 Recruiting
1,260 enrolled
MountainTAP-29
Phase 2/3 Recruiting
590 enrolled
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
Phase 1 Recruiting
331 enrolled
MK-3475-01A
Phase 1/2 Recruiting
450 enrolled
MK-3475-06D
Phase 1/2 Recruiting
210 enrolled
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 3 Recruiting
1,000 enrolled
MAESTRA 2
Phase 3 Recruiting
466 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
MK-2870-010
Phase 3 Recruiting
1,200 enrolled
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Phase 3 Recruiting
851 enrolled
TroFuse-011
Phase 3 Recruiting
1,000 enrolled
TroFuse-033
Phase 3 Recruiting
1,123 enrolled
TroFuse-036
Phase 3 Recruiting
1,023 enrolled
DE-01
Phase 3 Recruiting
600 enrolled
EmpowHER 208
Phase 2 Recruiting
125 enrolled
INTerpath-13
Phase 2 Recruiting
180 enrolled
INTerpath-009
Phase 3 Recruiting
680 enrolled
MK-3475-01E
Phase 2 Recruiting
60 enrolled
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Phase 1/2 Recruiting
72 enrolled
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Phase 3 Recruiting
572 enrolled
Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer
Phase NA Recruiting
24 enrolled
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Phase 2 Recruiting
110 enrolled
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Phase 2 Recruiting
42 enrolled
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Phase 3 Recruiting
700 enrolled
A Phase II Trial of LM103 in Advanced Melanoma
Phase 2 Recruiting
92 enrolled
MK-3475-06B
Phase 1/2 Recruiting
230 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
MRD
Phase 1/2 Recruiting
30 enrolled
OVATION-3
Phase 3 Recruiting
500 enrolled
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1 Recruiting
330 enrolled
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
880 enrolled
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Phase 3 Recruiting
540 enrolled
CheckMate-1533
Phase 2 Recruiting
76 enrolled
ALTAIR
Phase 1/2 Recruiting
152 enrolled
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Phase 1 Recruiting
500 enrolled
MK-3475-01G
Phase 2 Recruiting
90 enrolled
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Phase 2 Recruiting
230 enrolled
Study of INCB123667 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
604 enrolled
pompom
Phase 3 Recruiting
416 enrolled
ASPEN-09
Phase 1/2 Recruiting
80 enrolled
Fern-EC-01
Phase 3 Recruiting
480 enrolled
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Phase 1/2 Recruiting
594 enrolled
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Phase 3 Recruiting
524 enrolled
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
Phase 2 Recruiting
21 enrolled
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
Phase 3 Recruiting
566 enrolled